33 results on '"Gurney, Howard"'
Search Results
2. Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia
3. Dual‐energy x‐ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy
4. Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres
5. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
6. Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
7. Outcomes of retroperitoneal lymph node dissection for testicular cancer by a high volume surgeon from Australia: a case for centralisation
8. Patterns of care and outcomes of men with germ cell tumors in a high‐volume Australian center
9. Thyroid gland metastasis from renal cell carcinoma: a case series and literature review
10. Science and art of anticancer drug dosing: nine steps to personalised therapy
11. Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma
12. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
13. Nuances to precision dosing strategies of targeted cancer medicines
14. Clinical concepts for cabazitaxel in the management of metastatic castration‐resistant prostate cancer
15. Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival
16. Dose considerations for anti-cancer drugs in metastatic prostate cancer
17. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program
18. Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia
19. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
20. Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia
21. Racial disparity in metastatic renal cell cancer: The pharmaco‐anthropology of sunitinib
22. Challenges in the sequencing of therapies for the management of metastatic castration‐resistant prostate cancer
23. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer
24. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross‐sectional study
25. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective
26. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
27. Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*
28. Long-Term Follow-Up of Patients Treated with Intermittent Hormone Therapy for Advanced Prostate Cancer
29. Haemopoietic cell kinetics in humans treated with rGM‐CSF
30. The management of primary fallopian tube carcinoma
31. Bone metastases in hypernephroma. Frequency of scapular involvement
32. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
33. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.